Johns Hopkins to Conduct an Ivermectin Study with Hospitalized Patients Infected with COVID-19
The investigational interest in common and economical anti-parasitic drug ivermectin (Stromectol)
continues to grow now as the prestigious Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans to launch a clinical trial in June.
In hospitalized patients with SARS-CoV-2, the virus behind the COVID-19 pandemic,
the Baltimore, Maryland-based investigators
will compare the standard of care with bicalutamide or ivermectin.
They are joining a growing group of research centers in a search for effective and safe treatments.
This group is taking a noticeably different approach than the University of Kentucky study, which focuses on patients at home with milder cases of COVID-19.
Context
A growing number of research centers around the world are investigating the use of Ivermectin as a potential therapy targeting SARS-CoV-2.
The idea started thanks to a group of creative and out-of-the-box thinking scientists in Australia.
The word spread and now a number of companies, academic medical centers, and governments are exploring the use of the anti-parasitic drug as a possible therapy.
The upside could be huge:
the drug is inexpensive and available.
In fact, Merck even helps developing nations by giving the drug, called Stromectol, away in some cases.
Now Johns Hopkins investigates ivermectin and an anti-androgen drug known as Bicalutamide—used together or with another hormone to treat prostate cancer.
The Study
Planned to commence June 2020 for a year, theSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
will probe into whether bicalutamide or ivermectin can have an impact on hospitalized patients infected with SARS-CoV-2.
Led by Principal Investigator Catherine H. Marshall, MD, MPH, and a team of sub-investigators listed below,
the team will study two groups including one randomized group receiving Bicalutamide Casodex) 150 mg by mouth daily for seven (7) days versus plus the standard of care for COVID-19
versus
the use of versus a study group receiving Ivermectin (Stromectol/Soolantra/Sklice) 600 µg/kg (maximum dose of 60mg) by mouth daily for three days with the possibility of extension to six (6) days if still hospitalized and approved by the Data and Safety Monitoring Board.
Ivermectin: Satoshi Omura: Potential of antiparasitic drugs
Satoshi Omura/Nobel Prize says:
Ivermectin, an antiparasitic drug developed 40 years ago, may be effective against new coronavirus infections.
Since April of this year, such a news has come in.
Ivermectin:
Ivermectin is a parasite control drug.
Since 2012,
Such as HIV and dengue fever,
In general, against the virus called flavivirus,
It is effective in vitro (in vitro test),
I already knew it.
Flavivirus type:
The new coronavirus is also a type of flavivirus.
Starting with the research presentation in Australia,
America,
England,
France,
Spain,
Thailand,
Puerto Rico,
Bolivia,
Peru……
Clinical trials have begun at universities and hospitals around the world.
Johns Hopkins University, a mecca for infectious disease research, announced that it will start clinical research, and expectations are rising.
― Bungeishunju Special Article (Bunshun Online)
https://news.yahoo.co.jp/articles/f2c014a21714b637017e52cd66b39da7783b2b1c